An equally efficacious and safe alternative: The once-weekly carfilzomib-based therapy

Applying CAR T-cell therapy in hematological malignancies from clinical studies to the real-world practice

Promising real-world evidence of all-oral triplet combination of ixazomib, lenalidomide, and dexamethasone (IRd) for the treatment of rrMM

Bridging towards allogeneic stem-cell transplant with the early use of novel therapies in the relapsed/refractory acute lymphoblastic leukemia setting

Balancing efficacy and cardiovascular safety in chronic lymphocytic leukemia with acalabrutinib

The real-world use of ixazomib achieved stable disease for nearly 3 years, longer than in clinical trial

Real-world analysis found ixazomib triple therapy effective in the management of relapsed/refractory multiple myeloma

Denosumab as a well-tolerated and effective bone targeting treatment option for multiple myeloma patients with osteolytic lesions

Brentuximab vedotin serves as a viable option to combine with chemotherapy for advanced stage Hodgkin lymphoma

Bruton’s tyrosine kinase inhibitors delay disease progression and extend survival in patients with relapsed/refractory mantle cell lymphoma